Zylox-Tonbridge Medical Technology Co., Ltd.
歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT
LICENSING AND INVESTMENT AGREEMENTS WITH AVINGER INC.

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**", "**we**" or "**our**") on a voluntary basis to provide the shareholders and potential investors of the Company with latest business updates of the Group.

The Company is pleased to announce that, as an enhancement to the Company's peripheral-vascular interventional device portfolio, the Company has entered into a series of licensing and investment agreements (the "**Agreements**") with Avinger Inc. ("**Avinger**"), a U.S.-based innovative medical device company and a third party independent to the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). Based on the Agreements, the Company will:

- receive an exclusive right to localize, manufacture and commercialize the entire product family of optical coherence tomography ("**OCT**") consoles, OCT-guided peripheral vascular atherectomy devices and peripheral vascular chronic total occlusion-crossing ("**CTO-crossing**") devices developed by Avinger in Greater China (including Mainland China, Hong Kong, Taiwan and Macau);

- become an authorized OEM manufacturer of Avinger for licensed products to be sold by Avinger or its agents outside Greater China upon regulatory approval and/or filing;

- collaborate with Avinger to distribute certain peripheral vascular products developed by the Company in the United States and Germany; and

- invest US$15.0 million into Avinger in two tranches (US$7.5 million in each tranche, subject to the achievement of certain milestones and satisfaction of other closing conditions) by subscribing newly issued common shares and preferred shares of Avinger.

Avinger has been dedicated to developing and promoting peripheral artery disease ("**PAD**") treatment devices in the United States and Europe for many years. Its flagship products with disruptive technology licensed to the Company mainly include Pantheris, a series of OCT-guided peripheral vascular atherectomy device ("**Pantheris**"), which has been approved for the treatment of peripheral vascular diseases as well as in-stent restenosis ("**ISR**"), Ocelot and Tigereye, two series of OCT-guided peripheral vascular CTO-crossing devices ("**Ocelot**" and "**Tigereye**") and LightBox 3, the OCT imaging consoles. These series are the only PAD devices with real time imaging function worldwide. More importantly, Avinger has completed multiple clinical trials, including the VISION Study, INSIGHT Study and CONNECT Study, all of which have clearly showed the clinical safety and efficacy of the relevant devices. Based in California, the United States, Avinger has a mature manufacturing process, proven research and development capabilities and an experienced management team consisting of many industry veterans.

According to the market research data from Millennium Research Group, there were over 8 million PAD patients in the United States as of 2022. Atherectomy has become a common practice in the treatment, leading the Total Addressable Market of atherectomy device to reach around US$760 million in 2022. Compared to the U.S. market, the epidemiology data in China from the Chinese Expert Consensus published by relevant medical professional associations show that the population of PAD patients was approximately 40 million as of 2020 and is still growing rapidly. With the increasing penetration of drug-coated balloons in interventional procedures, the demand for better vessel preparation to optimize post-intervention results has grown substantially in the past several years.

Currently, atherectomy devices approved in China are not widely used due to the risk of intra-vascular damage. Physicians can only rely on fluoroscopy during procedure while having no intra-vascular vision. Meanwhile, all approved products are imported, whose higher prices limit the growth of their use in the Chinese market. With the introduction of Pantheris, a series of atherectomy devices with OCT function, physicians can see real-time intra-vascular images, which can tremendously reduce the risk of vascular damage as well as paving the way for further treatment with drug-coated balloons or stents.

Regarding CTO-crossing devices, the crossing tips of Ocelot and Tigereye series are also equipped with an OCT imaging system in order to clearly show the structure of the diseased vessel. These devices enhance the crossing success rate and maintain the true lumen (i.e. the original channel in the blood vessel), which are the key pain points for crossing guidewires.

The Company believes the collaboration with Avinger will enable both parties to better unlock the potential of and the unmet clinical needs for vessel disease treatment in China's peripheral vascular intervention market. The Company will leverage its extensive marketing and sales network to promote the advanced technologies developed by Avinger, thereby bringing high-quality and affordable innovative medical devices and solutions to a broader range of patients in China. We expect the localized manufacturing and supply of Avinger's products in China will help it lower production cost and provide it with cost advantage when competing in the global market. In addition, we expect to work with Avinger to explore synergies among products of both parties globally. The Company believes this collaboration is another key step for building our leading position in the PAD interventional device market. Upon the successful collaboration with Avinger, the Company will have a full portfolio to meet the clinical needs for CTO-crossing, vascular preparation and lesion treatment.

As the highest applicable percentage ratio under Rule 14.07 of the Listing Rules in respect of the Agreements and the transactions contemplated thereunder is less than 5%, the transactions contemplated under the Agreements do not constitute a notifiable transaction for the Company under the Listing Rules. This announcement is published by the Company on a voluntary basis.

By order of the board of directors
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, March 7, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive directors.